Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T | ISIN: JP3475350009 | Ticker-Symbol: D4S
Tradegate
27.06.25 | 09:28
19,885 Euro
+1,22 % +0,240
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
19,53019,80012:53
19,64019,93512:20

Aktuelle News zur DAIICHI SANKYO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAstraZeneca, Daiichi's Datroway scores its 2nd FDA approval-this time in lung cancer subset18
DAIICHI SANKYO Aktie jetzt für 0€ handeln
DiDaiichi Sankyo, AstraZeneca gets U.S. approval for Datroway3
DiAZ, Daiichi get Datroway nod in lung cancer on second try1
DiFDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer4
DiAstraZeneca/Daiichi Sankyo's Datroway granted FDA accelerated approval for lung cancer2
DiFDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC3
DiAstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M2
DiAstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer350LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed...
► Artikel lesen
DiUS approves AstraZeneca, Daiichi's treatment for lung cancer4
07.06.Daiichi, Shell partner for RE push25
04.06.Daiichi Sankyo struck gold with 'ADC' cancer drugs. Its new CEO has to figure out what's next.13
02.06.Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC9
31.05.AstraZeneca And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial1.316LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated...
► Artikel lesen
31.05.AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial4
30.05.Daiichi Sankyo and MSD withdraw US application for lung cancer BLA3
29.05.Merck, Daiichi pull approval application for ADC in lung cancer20
29.05.Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint5
29.05.MSD and Daiichi Sankyo pull HER3-DXd's FDA filing3
29.05.Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan605KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited...
► Artikel lesen
29.05.Merck, Daiichi Sankyo pull marketing application for lung cancer therapy5
Weiter >>
116 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1